Search

It is a major problem to remediate the uranium contaminated groundwater at an acid in-situ leaching uranium mine. In this paper, phytic acid was hydrolyzed by the hydrothermal reaction to obtain phytic acid hydrolyzate, and the simulated uranium contaminated groundwater was prepared according to the physicochemical characteristics of uranium-contaminated groundwater at an acid in-situ leaching uranium mine. The effect of the amount of added phytic acid hydrolyzate and its pH value on the removal performance of U( VI) from the uranium contaminated groundwater was explored, and the concentrations of phosphate anion, calcium ion, total iron ion, manganese ion, zinc ion, and magnesium ion were monitored, and the mechanism for the remediation of uranium contaminated groundwater was analyzed by SEM, TEM, XPS and XRD. The results show that when the amount of the addied phytic acid hydrolyzate was 2 mL, the concentration of phosphate was 24.562 g/L, the initial pH value was 6, the amount of simulated uranium contaminated groundwater was 100 mL, its initial pH value was 3, its uranium concentration was 5 mg/L, and the reaction time was 12 h, the removal rate of uranium reached more than 99%, and the pH value was raised to 5.9. The current research verified that it is feasible to use phytic acid hydrolyzate to remediate the uranium contaminated groundwater at add in-situ leading uranium mine. Since phytic add is cheap and easy to obtain, it can be used as an economical phosphorus source to replace expensive phosphate compounds for the remediation of uranium-contaminated groundwater at the mine. [ABSTRACT FROM AUTHOR]

Objective: To explore the clinical efficacies of bevacizumab (BEV) for high-grade glioma (HGG) in Chinese patients and evaluate its profiles of adverse events and usage safety., Methods: A total of 15 HGG cases, including glioblastoma multiform (GBM) (n = 12) and anaplastic astrocytoma (AA) (n = 3), were selected to receive the treatments of BEV (10 mg/kg, q2w) and temozolomide (TMZ, 150 mg/m(2), 5 d/28 d). Their radiological responses, clinical status, progression-free survival (PFS) and overall survival (OS) were evaluated. Also their adverse events and severity were recorded and analyzed., Results: According to the RANO criteria, during the short period (<3 months), 11 cases had significant radiological and clinical responses. However, only 4 cases responded during a follow-up period of beyond 3 months. Three cases had retrogression after BEV chemotherapy. At 6 months post-treatment, 8 cases (53.3%) survived without lesion progression and the median PFS was 8 ± 5 months. During a longer follow-up (>6 months), 8 patients had tumor retrogression, including 5 deaths. The median overall survival period was 24 ± 10 months. The adverse events included hypertension (n = 2), wound-healing complication (n = 1), vomiting (n = 2) and cerebro-spinal fluid leakage (n = 1). All complications were cured by activate supportive measures., Conclusion: After BEV treatment, most patients obtain more significant short-term responses with good toleration. For re-operative cases, the usage of BEV should be deferred to one month post-operation so as to avoid the occurrence of wound-healing complications.